Q4 2024 EPS Estimates for GSK plc Lifted by Analyst (NYSE:GSK)

GSK plc (NYSE:GSK) – Research analysts at Zacks Research lifted their Q4 2024 earnings estimates for shares of GSK in a research report issued to clients and investors on Tuesday, June 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $0.84 per share for the quarter, up from their previous forecast of $0.83. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.00 EPS.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The company had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion.

Other analysts also recently issued reports about the stock. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. The Goldman Sachs Group started coverage on shares of GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective for the company. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Finally, Citigroup raised shares of GSK to a “strong-buy” rating in a report on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, GSK currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

GSK Stock Performance

Shares of GSK opened at $38.66 on Friday. The company’s fifty day moving average is $42.55 and its 200-day moving average is $41.17. GSK has a 12 month low of $33.67 and a 12 month high of $45.92. The firm has a market cap of $80.12 billion, a price-to-earnings ratio of 14.01, a price-to-earnings-growth ratio of 1.17 and a beta of 0.66. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be issued a $0.3762 dividend. The ex-dividend date is Thursday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a yield of 3.89%. GSK’s dividend payout ratio is 53.26%.

Institutional Trading of GSK

Hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc boosted its holdings in GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 676 shares during the period. Register Financial Advisors LLC bought a new stake in GSK in the 1st quarter valued at $31,000. BKM Wealth Management LLC bought a new stake in GSK in the 4th quarter valued at $32,000. Richardson Financial Services Inc. bought a new stake in GSK in the 4th quarter valued at $40,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in GSK in the 1st quarter valued at $49,000. 15.74% of the stock is owned by institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.